Abstract 1151MO
Background
Major pathological response after neoadjuvant cisplatin-based chemotherapy for early-stage NSCLC has been shown to predict survival. This has not been demonstrated for neoadjuvant immune checkpoint inhibitors. In IONESCO multicenter phase II trial, 3 cycles of durvalumab were administered in stage IB>4cm–IIIA, non N2 resectable NSCLC (TNM 8th edition) before surgery. We report here the updated analysis on disease-free survival (DFS) and overall survival (OS) and their association with residual viable tumor cells (RVT).
Methods
Tissue specimens from patients who underwent neoadjuvant durvalumab and complete surgical resection were retrospectively evaluated by two pathologists blinded to patient outcomes. Specimens were reviewed for the degree of pathologic response i.e. % of RVT in the primary tumor and in any involved lymph nodes. The relationship between % of RVT as a continuous variable and outcomes (OS and DFS) was analyzed using a Cox regression model including patient characteristics (age, gender, PS, smoking status), histology, PD-L1 tumor proportion score (TPS), stage and surgical procedure.
Results
50 pts were included. 46 were eligible and received durvalumab, 43 operated, 67.4% males, median age, 61 yr; all ECOG PS 0-1; 98% (ex-)smokers; 23 adenocarcinoma, 19 squamous; clinical stages IB/IIA/IIB/IIIA = 5/13/27/1; 15 TPS ≥1%. Median % of RVT was 36.11. Median OS and DFS were not reached; 18-m OS: 89.1% [95% CI: 75.8-95.3] 18-m DFS: 73.7% [95% CI: 58.4-84.1]. In the multivariate prognostic analysis, for increasing value of % of RVT, OS and DFS were poorer (HR [95%CI]: 1.05 [1.00-1.10] p=0.04 and 1.06 [1.01-1.11] p=0.02, respectively).
Conclusions
The IFCT-1601 IONESCO trial showed for the first time that the extent of pathological response to a neoadjuvant immune checkpoint inhibitor is an independent prognostic factor of OS and DFS in NSCLC.
Clinical trial identification
NCT03030131.
Editorial acknowledgement
Legal entity responsible for the study
French Cooperative Thoracic Intergroup (IFCT).
Funding
AstraZeneca.
Disclosure
M. Wislez: Non-Financial Interests, Institutional, Principal Investigator: AstraZeneca; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Institutional, Funding: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: Roche; Non-Financial Interests, Institutional, Principal Investigator: BMS; Financial Interests, Personal, Speaker’s Bureau: BMS; Non-Financial Interests, Institutional, Principal Investigator: MSD; Financial Interests, Personal, Advisory Board: MSD; Non-Financial Interests, Institutional, Principal Investigator: Novartis; Financial Interests, Personal, Advisory Board: Novartis; Non-Financial Interests, Institutional, Principal Investigator: Lilly; Non-Financial Interests, Institutional, Principal Investigator: Merck KGaA; Non-Financial Interests, Institutional, Principal Investigator: Merus; Non-Financial Interests, Institutional, Principal Investigator: GSK; Non-Financial Interests, Institutional, Principal Investigator: Amgen; Financial Interests, Personal, Speaker’s Bureau: Boeringher Ingelheim. J. Mazieres: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Daiichi; Financial Interests, Personal, Advisory Board: Pierre Fabre; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Institutional, Research Grant: Pierre Fabre. G. Zalcman: Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Advisory Board: AstraZeneca; Financial Interests, Personal, Other, Meeting attendance reimbursement: Pfizer; Financial Interests, Institutional, Advisory Board: MSD; Financial Interests, Institutional, Advisory Board: Da Volterra; Financial Interests, Institutional, Advisory Role: Inventiva; Financial Interests, Institutional, Principal Investigator: AbbVie; Financial Interests, Institutional, Principal Investigator: GSK; Financial Interests, Institutional, Principal Investigator: BMS; Financial Interests, Institutional, Principal Investigator: Roche; Financial Interests, Institutional, Principal Investigator: AstraZeneca; Financial Interests, Institutional, Principal Investigator: Da Volterra. O. Molinier: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Other, Teaching: Menarini. V. Westeel: Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Other, Honoraria: BMS; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: Takeda; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: BMS; Financial Interests, Personal, Speaker’s Bureau: MSD; Financial Interests, Personal, Speaker’s Bureau: Roche; Financial Interests, Institutional, Research Grant: Boehringer Ingelheim; Financial Interests, Institutional, Research Grant: MSD; Financial Interests, Personal, Other, Travel, Accomodation, Expenses: AstraZeneca; Financial Interests, Personal, Other, Travel, Accomodation, Expenses: BMS; Financial Interests, Personal, Other, Travel, Accomodation, Expenses: Pfizer; Financial Interests, Personal, Other, Travel, Accomodation, Expenses: Roche. D. Damotte: Financial Interests, Institutional, Advisory Board: AstraZeneca; Financial Interests, Personal and Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Personal, Advisory Board: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
1732MO - Pembrolizumab and nintedanib for patients with advanced mesothelioma
Presenter: François-Xavier Danlos
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA43 - GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)
Presenter: Yi-Long Wu
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1171MO - PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Presenter: Nicolas Girard
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA61 - Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study
Presenter: Luis Paz-Ares
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1172MO - Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations
Presenter: Mariona Riudavets Melia
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
Discussion 1151MO and 1732MO
Presenter: Michael Thomas
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
Discussion LBA43 and 1171MO
Presenter: Lizza Hendriks
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
Discussion LBA61 and 1172MO
Presenter: Alfredo Addeo
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast